Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $17.3 million.

  • Amphastar Pharmaceuticals' Profit After Tax fell 5708.53% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year decrease of 2922.42%. This contributed to the annual value of $159.5 million for FY2024, which is 1597.59% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Profit After Tax is $17.3 million, which was down 5708.53% from $31.0 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Profit After Tax high stood at $49.2 million for Q3 2023, and its period low was $5.0 million during Q1 2021.
  • Its 5-year average for Profit After Tax is $27.7 million, with a median of $26.1 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first soared by 70335.9% in 2021, then tumbled by 5708.53% in 2025.
  • Amphastar Pharmaceuticals' Profit After Tax (Quarter) stood at $19.8 million in 2021, then skyrocketed by 71.62% to $33.9 million in 2022, then grew by 6.65% to $36.2 million in 2023, then rose by 4.97% to $38.0 million in 2024, then tumbled by 54.3% to $17.3 million in 2025.
  • Its Profit After Tax was $17.3 million in Q3 2025, compared to $31.0 million in Q2 2025 and $25.3 million in Q1 2025.